Biodesix, Inc.
BDSX
$7.30
-$0.24-3.18%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 76.56M | 74.46M | 71.32M | 65.56M | 60.90M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 76.56M | 74.46M | 71.32M | 65.56M | 60.90M |
| Cost of Revenue | 16.26M | 16.10M | 15.57M | 14.61M | 13.66M |
| Gross Profit | 60.30M | 58.36M | 55.75M | 50.96M | 47.25M |
| SG&A Expenses | 83.09M | 80.34M | 80.45M | 76.48M | 71.96M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 110.45M | 106.83M | 105.58M | 100.12M | 94.04M |
| Operating Income | -33.89M | -32.37M | -34.26M | -34.56M | -33.14M |
| Income Before Tax | -41.08M | -40.42M | -42.93M | -43.82M | -44.51M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -41.08 | -40.42 | -42.93 | -43.82 | -44.51 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -41.08M | -40.42M | -42.93M | -43.82M | -44.51M |
| EBIT | -33.89M | -32.37M | -34.26M | -34.56M | -33.14M |
| EBITDA | -28.08M | -26.58M | -28.49M | -29.26M | -28.55M |
| EPS Basic | -5.61 | -5.74 | -7.03 | -7.88 | -9.23 |
| Normalized Basic EPS | -3.49 | -3.54 | -4.35 | -4.88 | -5.73 |
| EPS Diluted | -5.61 | -5.74 | -7.03 | -7.88 | -9.23 |
| Normalized Diluted EPS | -3.49 | -3.54 | -4.35 | -4.88 | -5.73 |
| Average Basic Shares Outstanding | 29.31M | 28.33M | 25.86M | 23.15M | 19.82M |
| Average Diluted Shares Outstanding | 29.31M | 28.33M | 25.86M | 23.15M | 19.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |